Gerresheimer AG is a global provider of primary packaging and drug delivery systems, primarily serving the pharmaceutical, biotechnology, and cosmetics sectors. The company operates through three main divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices segment, which accounts for approximately 56% of revenues, manufactures complex, customer-specific products for drug delivery, such as insulin pens, inhalers, and prefillable syringes, alongside plastic packaging for liquid and solid medicines. The Primary Packaging Glass segment, generating around 44% of revenues, produces specialized glass containers including vials, ampoules, cartridges, and bottles. The Advanced Technologies division focuses on technical and digital solutions, such as wearable micro-pumps and smart drug delivery systems.
Geographically, Gerresheimer generates the majority of its revenue in Europe (approximately 60%) and the United States (around 27%), operating over 40 manufacturing facilities across 16 countries in Europe, the Americas, and Asia. The company's business model relies on long-term supply relationships with major pharmaceutical and biotech companies, providing essential components that meet strict regulatory and sterility standards. In 2024, Gerresheimer expanded its capabilities and market presence by acquiring Bormioli Pharma, adding complementary glass and plastic packaging assets to its portfolio. By sitting at the intersection of materials science and healthcare, Gerresheimer plays a critical role in the safe and reliable administration of therapeutics worldwide.
